ABBV-951 is subcutaneous delivery of Levodopa/Carbidopa being investigated for the treatment of Parkinson’s disease.
Type of Molecule
Small Molecule
Target
Dopamine Receptor
Region
n/a
| Potential Indication | Product Type | Phase (1, 2, 3, Submitted, Approved) |
|---|---|---|
| Parkinson's Disease | New Indication | Phase 1 |